Immunotherapy in Advanced Solid Tumour
Received Date: Apr 08, 2022 / Published Date: Jun 13, 2022
Abstract
With the evolving understanding of the interaction between tumor and the immune system, novel therapies with sophisticated mechanisms of action are establishing themselves as the standards of care. In human cancer, the immune system plays a double edged sword with both protecting against tumor development as well as promoting tumor growth. In recent times innumerable practice-changing clinical studies have being reported on immunotherapy. In this review article, we highlight the recently approved immunotherapy and chemotherapy combination in adjuvant and 1st line metastatic setting in various solid tumors except renal cell carcinoma and melanoma.
Keywords: Gastroesophageal; Chemoradiotherapy; Pembrolizumab; Nivolumab
Citation: Badola A (2022) Immunotherapy in Advanced Solid Tumour. J Oncol Res Treat 7: 192.
Copyright: © 2022 Badola A. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Share This Article
黑料网 Journals
Article Usage
- Total views: 1460
- [From(publication date): 0-2022 - Nov 25, 2024]
- Breakdown by view type
- HTML page views: 1252
- PDF downloads: 208
